Aligos Therapeutics, Inc.
ALGS
$5.45
-$0.38-6.52%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -194.53% | -6.75% | 126.93% | -51.88% | -27.44% |
| Total Depreciation and Amortization | -13.42% | -2.06% | -20.68% | -20.14% | -13.60% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 1,235.56% | -48.14% | -877.97% | 398.59% | 42.23% |
| Change in Net Operating Assets | -33.11% | 48.69% | 539.35% | -49.58% | -133.87% |
| Cash from Operations | 18.78% | 1.16% | -43.16% | -1.60% | -35.01% |
| Capital Expenditure | -300.00% | -116.67% | -200.00% | -885.71% | 92.31% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | 104,140.00% | 60.06% | -542.87% | -100.00% |
| Cash from Investing | 285,414.29% | 115,633.33% | 59.95% | -543.37% | -100.06% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -975.00% | 76.19% | 65.96% | 20.83% | -114.81% |
| Issuance of Common Stock | -99.20% | -- | -35.57% | -- | 18,552.13% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -99.89% | 80.95% | -32.13% | -1,800.00% | 72,574.38% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -97.45% | 52.34% | 76.08% | -4,551.65% | 1,390.45% |